Phase 1b, Multicenter, Open-Label Study of Marizomib with Temozolomide and Radiotherapy in Patients with Newly Diagnosed WHO Grade IV Malignant Glioma. MRZ112

Administered By

Duke Cancer Institute

Awarded By

Triphase Research and Development Corp

Contributors

Desjardins, Annick Principal Investigator

Start/End

December 1, 2016 - March 31, 2020